Net Income

With near-zero revenue and a history of pivots, 1606 Corp. is betting its future on solving AI's energy crisis. Can it pull off this risky venture?

A novel three-in-one antibody from CStone shows a 90% response rate in lung cancer and potent activity in 'cold tumors,' heralding a new era for immunotherapy.

Genesys reports record growth fueled by its AI platform, signaling a major shift in how businesses manage customer service and agent productivity.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

Dubai hits its highest-ever rank in the Global Financial Centres Index, solidifying its MEASA dominance and fast-tracking its D33 vision to join the elite.

After a turbulent year, Tidewater Renewables projects a major profit surge in 2026, fueled by operational fixes and powerful government support programs.

Autonomous driving firm Pony.ai announces a first-ever quarterly profit and a bold plan to deploy 3,000 robotaxis globally by the end of 2026.

As AI pushes Canada's grid to the brink, a firm pivots from steel to hydrogen, joining an alliance to solve the data centre energy crisis.

DURABOOK's new Z14I-HG is the world's first fully rugged mobile workstation with massive AI power, bringing data center performance to extreme environments.

Despite revenue growth, ICAPE Group posts a net loss after deciding to close two plants, signaling a pivot to a leaner model focused on innovation.

As big banks retreat, private lenders and small investors are revitalizing neighborhoods and adding homes to a market in desperate need of supply.

The company's B-cell cancer assay has achieved stringent IVDR certification, navigating a complex landscape and gaining a key edge in Europe's market.

With revenues up but losses widening, Arverne Group is aggressively investing in geothermal energy and lithium to secure France's energy independence.

The enclosure manufacturer reversed a 2024 loss, reporting a $282,000 profit for 2025 on a 30.7% revenue surge, signaling a strong market recovery.

Strong product sales and innovation clash with a steep service decline in Europe, forcing Enerpac to restructure and adjust its outlook for 2026.

The successful launch of rosacea treatment Emrosi™ generated $14.7M, driving Journey Medical's revenue to $61.9M and signaling a major strategic win.

Adhesives giant H.B. Fuller expands margins and raises its 2026 outlook, signaling operational strength amid market softness and supply chain turmoil.

The smart glasses maker reports record sales driven by niche products, yet continued investment in global expansion keeps the company in the red for now.

Armata Pharmaceuticals posts a staggering $174M annual loss, triggering a 'going concern' alert, yet its promising phage therapy pipeline advances.

Fueled by a $250K grant from Allen Family Philanthropies, a new pilot aims to tackle Seattle's infamous social isolation with a structured national plan.